Biopharma firm I-Mab tees up $100m ADS listing

Cancer_cell_29March2017_Fotolia_230x150
By Jonathan Breen
30 Oct 2019

Chinese biopharmaceutical firm I-Mab has set the ball rolling for a potential $100m Nasdaq IPO, having filed a prospectus with the US regulator on Tuesday.

The company has hired CICC and Jefferies to lead its IPO of American Depository Shares (ADS), while China Renaissance and Huatai Securities (USA) are junior members of the syndicate.

I-Mab is a clinical stage biopharmaceutical firm that focuses on developing and commercialising treatments primarily for cancer and autoimmune ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial